Dyne Therapeutics jobs

Associate Director, Omnichannel Enablement Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Associate Director, Omnichannel Enablement will be a critical leader in building and scaling Dyne's omnichannel capability to support disease area readiness, launch excellence, and sustained commercial growth. This role will be accountable for bringing omnichannel strategy to life through the hands-on design and implementation of customer journeys, modular content frameworks, and activation models that enable coordinated, personalized, and insight-driven engagement across channels. The Associate Director will work directly with brand teams and enabling functions to translate strategy into practical execution-designing journeys, shaping content approaches, and embedding omnichannel ways of working into day-to-day operations. This role will partner closely with Commercial Strategy, Brand Marketing, Commercial Insights & Analytics, Field Excellence, IT/Digital, and external partners to ensure omnichannel is delivered as a scalable, repeatable capability. This role is based in Waltham, MA, without the possibility of being a fully remote role. Primary Responsibilities

Director, QA GMP Operations Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Director of QA GMP Operations is responsible for management of GMP quality within our external manufacturing operations globally and internal GMP operations for development and commercial programs. The Director will also work closely with internal business stakeholders as well as internal Quality function to deliver outcomes to advance programs within compliance. The Director is responsible for oversight of QA activities and ensuring the quality of deliverables within the role's purview. This is an onsite role based in Waltham, MA. Primary Responsibilities Include : Management of external quality operations in support of GMP manufacturing (clinical and commercial) activities. Manage deviations, OOS and OOTs investigations while adhering to cGMP principles and ICH guidelines. Review batch records, analytical method reports and technical reports including regulatory sections of IND/IMPD and BLA/MAAs. QA support of Tech Transfer and Process Validation activities. Disposition of GMP batches and

Duro Dyne Senior Product Leader Bay Shore, NY, US Who We Are Duro Dyne , established in 1952, has evolved into the leading manufacturer of sheet metal accessories and equipment for the HVAC industry. For over 70 years, Duro Dyne has expanded its plant locations and now employs over 200 people. Duro Dyne National Corporation is committed to providing superior quality and unparalleled dedication to all aspects of our business. We believe every employee contributes to the success and growth of our company. As an employee at Duro Dyne, you reap the benefits of being part of an expanding company that still maintains a progressive employee culture and atmosphere. Lennox (NYSE: LII) Driven by 130 years of legacy, HVAC and refrigeration success, Lennox provides our residential and commercial customers with industry-leading climate-control solutions. At Lennox, we win as a team, aiming for excellence and delivering innovative, sustainable products and services. Our culture guides us and creates a workplace where all employees feel heard and welcomed. Lennox is a global community that values each team member's contributions and offers a supportive environment for career development. Come, stay, and grow with us. What Drives Success We are seeking a strategic and experienced Senior Product Leader to oversee and elevate all aspects of Product Management within the organization. This role is responsible for leading cross-functional teams and driving product strategy, development, and execution to align with business objectives and custom

Senior Director, Clinical Development Remote About Us We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology - enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation - enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . About the Role The Senior Medical Director, Clinical Development will be the clinical and medical strategic lead of one or more clinical trials for DNTH212. Reporting to the SVP, Clinical Development, you will steer the preparation, review and execution of clinical study synopses and protocols, investigator brochures, and clinical study reports; review SAPs and TLF shells, guide the evaluation of emerging clinical trial data, oversee/guide the data interpretation and data mining, and ensure assigned studies are conducted according to GCPs and SOPs. You will act as a the medical monitor in close collaboration with the CRO medical and clinical monitors, ensure timely recruitment in collaboration with clinical operations, oversee/guide in conducting literature searches and reviews, meta-analyses, and publishing data. You must have experience with Rare Diseases or Rheumatology within the biotechnology or pharmaceutical

Associate Director, Pharmacovigilance Remote About Us We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology - enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation - enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . About the Role As the Associate Director, Pharmacovigilance, you will work closely with the Safety team to support ongoing clinical trials. This role is critical in ensuring patient safety and regulatory compliance throughout the drug development lifecycle. Day to day, you will work closely with safety physicians, clinical teams, and external stakeholders to manage safety data and contribute to safety oversight. You must have experience reviewing adverse events, safety signals, and coordinate/contribute to the Safety Review Committee (SRC) and Drug Safety Monitoring Boards (DSMB) meetings. You must have experience supporting clinical pharmacovigilance activities and working with DSMBs in order to be successful in this role. This is a unique role that will allow you to work collaboratively with the growing pharmacovigilance team that is working closely with cross functional teams to help Dianthus elevate

Territory Manager - Duro Dyne Seattle, WA, US; Portland, OR, US; Boise, ID, US Who We Are Lennox (NYSE: LII) Driven by 130 years of legacy, HVAC and refrigeration success, Lennox provides our residential and commercial customers with industry-leading climate-control solutions. At Lennox, we win as a team, aiming for excellence and delivering innovative, sustainable products and services. Our culture guides us and creates a workplace where all employees feel heard and welcomed. Lennox is a global community that values each team member's contributions and offers a supportive environment for career development. Come, stay, and grow with us. Established in 1952, the Duro Dyne National Corporation, has evolved into the leading manufacturer of sheet metal accessories and equipment for the HVAC industry. For over 70 years, Duro Dyne has expanded its plant locations and now employs over 200 people. Duro Dyne National Corporation is committed to providing superior quality and unparalleled dedication to all aspects of our business. We believe every employee contributes to the success and growth of our company. As an employee at Duro Dyne, you reap the benefits of being part of an expanding company that still maintains a progressive employee culture and atmosphere. What Drives Success As a Territory Manager , you will play a critical role in driving growth across your assigned region by identifying new business opportunities and cultivating strong, long-term relationships with existing customers. You'll be responsible for increasing sales of our products and servi

National Accounts Manager – Parts & Supplies Richardson, TX, US; Atlanta, GA, US; New York, NY, US; Phoenix, AZ, US Who We Are Lennox (NYSE: LII) Driven by 130 years of legacy, HVAC and refrigeration success, Lennox provides our residential and commercial customers with industry-leading climate-control solutions. At Lennox, we win as a team, aiming for excellence and delivering innovative, sustainable products and services. Our culture guides us and creates a workplace where all employees feel heard and welcomed. Lennox is a global community that values each team member's contributions and offers a supportive environment for career development. Come, stay, and grow with us. Established in 1952, the Duro Dyne National Corporation , has evolved into the leading manufacturer of sheet metal accessories and equipment for the HVAC industry. For over 70 years, Duro Dyne has expanded its plant locations and now employs over 200 people. Duro Dyne National Corporation is committed to providing superior quality and unparalleled dedication to all aspects of our business. We believe every employee contributes to the success and growth of our company. As an employee at Duro Dyne, you reap the benefits of being part of an expanding company that still maintains a progressive employee culture and atmosphere. SUPCO (Sealed Unit Parts Co.,Inc.) is a leading manufacturer and master distributor of high-quality innovative products designed for the heating, ventilating, air conditioning, refrigeration and appliance parts industries. In business since 1945, they have established themselves as the premiere name in

Associate Director, Drug Substance Development & Manufacturing Boston, MA The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670). We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families. The Perfect Addition to Our Team You are a motivated, resourceful, and enthusiastic Drug Substance Development & Manufacturing expert excited to support the

Senior Clinical Trial Associate (CONTRACT) Boston, MA The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670). We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families. The Perfect Addition to Our Team You are patient focused and excited about the opportunity to help support and develop the Clinical Operations organization at

Director of Process Validation Viking Therapeutics, Inc. Director of Process Validation

Associate Director, Clinical Development Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! The Associate Director, Clinical Development plays a key role in the design and execution of ongoing and new clinical development studies. This position serves as the clinical science representative on one or more U.S. and/or global clinical studies and contributes to the delivery of high‑quality clinical data to support registration and launch. The role partners cross‑functionally with Clinical Operations, Clinical Pharmacology, Regulatory Affairs, Early Development,

Drug Safety Manager Viking Therapeutics, Inc. Drug Safety Manager

Head of DMPK San Francisco, CA tl;dr General Proximity is a seed-stage startup developing the next generation of induced proximity medicines (IPMs). Our OmniTAC drug discovery engine furnishes molecules that co-opt existing cellular machinery to overcome therapeutic challenges, which have remained unapproachable to other modalities for decades. We are seeking a first-rate DMPK expert to help us pioneer this uncharted frontier of drug discovery. Our Story A long-standing challenge in drug discovery is the development of molecules capable of modulating difficult or "undruggable" targets. Disease-causing proteins can be dysfunctional in many different ways, but our armamentarium for fixing them is quite limited. The most common mechanism of action for FDA-approved drugs is inhibition [1] , but there are many other possible perturbation types whose potential remains unrealized. General Proximity is a seed-stage drug discovery company developing a novel platform technology to solve this problem. We make bifunctional drugs that induce the modification of drug targets by existing cellular machinery (rather than through direct modulation by the drug, the classical approach). Historically, the development of technologies that allow one to push new buttons in biology has been an incredibly fertile field for the discovery of new medicines[ 2 , 3 , 4 ], and our technology holds the same promise. The Position We are seeking an experienced Head of DMPK to lead and shape our drug metabolism and pharmacokinetics function. This is a high-impact leadership role in which you will own the DMPK strategy across our small molecule portfolio, build and

Clinical Trial Manager Viking Therapeutics, Inc. Clinical Trial Manager

Senior Director, Marketing Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! Definium Therapeutics, formerly known as Mind Medicine, is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key

Medical Science Liaison Director/Lead Viking Therapeutics, Inc. Medical Science Liaison Director/Lead

Associate Director/Director, Technical Operations - Drug Substance (Small Molecules) New York, NY Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X . About This Role: Axsome Therapeutics is seeking an Associate Director/Director, Technical Operations - Drug Substance (Small Molecules) to provide technical leadership across the development and commercial lifecycle of small‑molecule drug substance programs. This role is responsible for supporting and overseeing drug substance manufacturing activities, including technology transfer, process validation, continued process verification (CPV), and post‑approval process changes at internal and external manufacturing sites. The successful candidate will serve as a key technical leader within CMC, partnering closely with external CDMOs and internal cross‑functional teams (QA, QC, Regulatory, R&D, and Supply Chain) to ensure robust, compliant, and efficient manufacturing operations. This position reports into senior

Associate Director, Formulation Development Viking Therapeutics, Inc. Associate Director, Formulation Development

Executive Director / Vice President, Corporate and Internal Communications - BioPharma Remote About Us We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology - enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation - enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . About the Role BioPharma Experience is required. We are seeking a strategic, creative, and execution-oriented ED / VP, Corporate & Internal Communications to build and lead a modern, high-impact communications function in a fast-growing biotech company. This role sits at the intersection of people, corporate brand, and business strategy-responsible for shaping how we communicate internally and externally, strengthening employee engagement, elevating our corporate brand, and ensuring a consistent and compelling company narrative across all audiences, while operating as predominantly a remote company. You will serve as a trusted advisor to senior leadership and partner closely with the VP of Marketing and VP of Investor Relations to ensure alignment across corporate and internal communications. We are building a culture of individuals who hold our core principles at

Senior/Executive Director, Health Economics & Outcomes Research (HEOR) Viking Therapeutics, Inc. Senior/Executive Director, Health Economics & Outcomes Research (HEOR)

Manager, Market Intelligence and Strategy Boston, MA The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670). We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families. The Perfect Addition to Our Team You are interested in working at the intersection of life sciences and business. You want to join a high

Therapeutic Mentor Bradenton, Florida posted: Posted 2 Days Ago

Vice President, Commercial Manufacturing Operations Remote Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics' lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com . Our values are the cornerstone of our culture. Our values inspire us every day and guide everything we do-from how we hire great people, to advancing our mission together, to achieving our ultimate goal to improve medical treatment for patients suffering from immunological diseases. Position Summary: The Vice President, Manufacturing Operations will report

DMPK Scientist Remote, Hybrid, New Haven - CT Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the